IMMUPHARMA - Key Persons

Job Titles:

• Chief Executive Officer ( Stepped Down

Job Titles:

• Member of the Board of Directors
• Member of the Management Team
• Senior Non - Executive Director
• Senior Non - Executive Director ( Appointed

Sanjeev has over 25 years of healthcare and international management experience. Sanjeev was formerly CEO of Advanced Oncotherapy Plc, a specialist cancer radiotherapy business listed on AIM. During his leadership, Sanjeev raised over $100m and developed and secured partnerships in the USA, EU, China, Singapore, India, Australia, Asia and South America. Formerly, Sanjeev had a number of leadership roles in several global clinical trials at Pfizer and was head of Europe Regulatory and Medical at Reckitt Benckiser.</p> <p>Formerly Sanjeev trained and worked as an orthopedic surgeon in the NHS and various Third World countries.</p> <p>Sanjeev has a medical degree from Trinity College, Cambridge and an MBA from INSEAD.

Job Titles:

• Chief Operating Officer
• Member of the Board of Directors
• Member of the Management Team
• Chief Operational Officer ( Appointed on 16 July

Tim has 30 years' experience in the biopharmaceutical industry. He worked in clinical research, sales & marketing, and global strategic marketing for Warner Lambert, Wellcome and SmithKline Beecham. He later moved to the capital markets where he became a top-ranked pharmaceuticals analyst at Dresdner Kleinwort investment bank. He applied his experience to stock selection at hedge funds and advised several small biotechnology companies on corporate and commercial strategy and access to capital. He holds a BSc in Medicinal Chemistry and a PhD in Pharmacology from Loughborough University and an MBA from Warwick Business School.

Job Titles:

• Founder of Lupuzor, Presents at Osaka University, Japan

ImmuPharma PLC (LSE: IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announce that Dr. Sylviane Muller was recently invited by the Immunology Frontier Research Center of Osaka University, an internationally renowned research center in the field of immunology, to hold a seminar on the approach of Lupuzor for treating lupus patients. The details of her abstract have now been released.

Job Titles:

• Research Director at CNRS

Dr. Sylviane Muller, Research Director at CNRS, Strasbourg, France is the key inventor of Lupuzor. Her abstract was titled "Chaperone-mediated autophagy as a target of therapeutic P140 peptide used in lupus". Her presentation focused partly on the on the highly competitive and efficacious mode of mechanism of LupuzorTM (also known scientifically as P140), ImmuPharma's potential blockbuster drug for Lupus, a chronic autoimmune disease. LupuzorTM has received Special Protocol Assessment and Fast Track Designation from the FDA for a Phase III trial.

Job Titles:

• Senior Non - Executive Director ( Stepped Down

Job Titles:

• Member of the Management Team
• Chief Scientific Officer of ImmuPharma Biotech

Job Titles:

• Head of Investor Relations
• Member of the Board of Directors
• Member of the Management Team
• Non - Executive Director
• Head of Investor Relations and Non - Executive Director ( Appointed

Lisa has spent over 25 years working within the City of London being involved with a diverse portfolio of clients from a variety of sectors but with a leaning towards emerging, high growth businesses advising both private and public companies on their financial and corporate strategies aligned to stakeholder and investor interests, as well as a strong acumen in media communication. During this time, she has been involved in a multitude of client transactions spanning private fund raisings, Initial Public Offerings (IPOs), secondary high profile capital raisings and mergers and acquisitions both in the UK and internationally.</p> <p>Lisa had a successful career spanning 20 years as a Partner at Buchanan Communications, one of the leading City financial public relations agencies. As one of the youngest Board members, she was involved in the successful five-year earnout, as part of Buchanan being acquired by the FTSE 100 rated WPP Plc in 1997.</p> <p>Lisa founded Just B Communications Ltd in 2012 with the key objective of working with a more select number of clients and providing a greater degree of bespoke advisory services thus becoming more integral to the day to day corporate and strategic development for these businesses. She has successfully advised a number of public and private companies, at Board level, on corporate strategy, stakeholder and investor communications, capital raisings, dual listings, licensing and M&A. Media profiling, where required, has also played an important role in advisory activities.</p> <p>Lisa was appointed Head of Investor Relations at ImmuPharma in 2012 and most recently appointed as a Non-Executive Director in July 2021.

Job Titles:

• Chairman
• Chief Executive Officer
• Member of the Board of Directors
• Member of the Management Team
• Chief Executive Officer and Chairman - 20 / 20

Tim has 40 years' international senior level business experience in high growth biotech, healthcare and technology companies. He is also Chairman of Incanthera plc and 4basebio plc. Tim was formerly CEO and CFO of a number of UK public listed and private companies including, including Alizyme plc and Peptide Therapeutics Group plc, and has a core understanding of AIM and its regulatory processes. Co-founding a number of healthcare and biotechnology companies, he has helped raise substantial amounts of equity capital and also advised and worked at Board level for a diverse range of companies internationally, in areas such as business strategy, mergers & acquisitions, due diligence and licensing. Tim McCarthy, Chairman and Chief Executive Officer, has assumed responsibility for ensuring that the Group has appropriate corporate governance standards and that these standards are applied throughout the Group. Tim Franklin, Chief Operational Officer (appointed on 16 July 2021) - 7/20

Job Titles:

• President and Chief Scientific Officer ( Stepped Down

Job Titles:

• Non - Executive Director ( Stepped Down

Principle 6 - Ensure that between them the directors have the necessary up-to-date experience, skills and capabilities The Board has extensive mixture of skills and experience, which enable the delivery of Group's strategy for the shareholders over the medium to long-term. These include scientific expertise, public market requirements, business acumen and financial knowledge. Please refer to Director biographies on pages 23 and 24. Principle 7 - Evaluate board performance based on clear and relevant objectives, seeking continuous improvement Internal evaluation of the Board, the Audit Committee and Remuneration Committee as well as individual directors is undertaken on an informal basis at present. The review takes the form of peer appraisal and discussions to determine the overall effectiveness of individual directors and the Board as a whole. Specific consideration will be given to evaluating the continued independence of the Group's non-executive directors. Senior management appointments are discussed at the Board Meetings and are managed by the Chief Executive Officer and Chief Operational Officer with additional support from Non-Executive Directors where appropriate.

Job Titles:

• Member of the Management Team
• Chief Executive Officer of ImmuPharma Biotech

Born in Sherbrooke, Québec, Canada, Dr Goudreau obtained his PhD in Chemistry at the Université of Montréal as a NSERC fellow before moving to Switzerland to conduct postdoctoral studies at the ETH Zürich as an FRQNT fellow. He then moved back to Canada for one year where he co-founded FindMolecule inc. and worked for the pharma industry.</p> <p>In 2014 he joined ImmuPharma as research director and established the research laboratories of Ureka in Bordeaux. After the merger of ELRO with Ureka in 2019, Dr Goudreau became Chief Scientific Officer of Ureka Pharma and in 2021, he became Chief Executive Officer of ImmuPharma Biotech. Notably, Dr Goudreau and his team are credited for the discovery and development of, among others, URK 614, BioGlucagon, and BioAMB.